June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Effect of CTG repeat expansion in TCF4 on the pathophysiology of Fuchs endothelial corneal dystrophy
Author Affiliations & Notes
  • Hinata Matsuo
    Biomedical Engineering,Doshisha University, Kyotanabe, Kyoto, Japan
  • Naoki Okumura
    Biomedical Engineering,Doshisha University, Kyotanabe, Kyoto, Japan
  • Yuya Komori
    Biomedical Engineering,Doshisha University, Kyotanabe, Kyoto, Japan
  • Ayumi Tokunaga
    Biomedical Engineering,Doshisha University, Kyotanabe, Kyoto, Japan
  • Genta Nakayama
    Biomedical Engineering,Doshisha University, Kyotanabe, Kyoto, Japan
  • Makiko Nakahara
    Biomedical Engineering,Doshisha University, Kyotanabe, Kyoto, Japan
  • Derek J Blake
    Psychological Medicine and Clinical Neurosciences, Cardiff University, United Kingdom
  • Theofilos Tourtas
    Ophthalmology, University of Erlangen-Nürnberg, Germany
  • Ursula Schlötzer-Schrehardt
    Ophthalmology, University of Erlangen-Nürnberg, Germany
  • Friedrich E Kruse
    Ophthalmology, University of Erlangen-Nürnberg, Germany
  • Noriko Koizumi
    Biomedical Engineering,Doshisha University, Kyotanabe, Kyoto, Japan
  • Footnotes
    Commercial Relationships   Hinata Matsuo, None; Naoki Okumura, ActualEyes, Inc. (F), ActualEyes, Inc. (I), Doshisha University (F), Doshisha University (P), Kowa Company Ltd. (C), Senju Pharmaceutical Co.,Ltd. (P); Yuya Komori, None; Ayumi Tokunaga, None; Genta Nakayama, None; Makiko Nakahara, None; Derek Blake, None; Theofilos Tourtas, None; Ursula Schlötzer-Schrehardt, None; Friedrich Kruse, None; Noriko Koizumi, ActualEyes, Inc. (F), ActualEyes, Inc. (I), Doshisha University (F), Doshisha University (P), Japan Innovative Therapeutics, Inc. (F), Kowa Company Ltd. (F), Kowa Company Ltd. (C), Senju Pharmaceutical Co.,Ltd. (F), Senju Pharmaceutical Co.,Ltd. (R), Senju Pharmaceutical Co.,Ltd. (P)
  • Footnotes
    Support  Program for the Strategic Research Foundation at Private Universities from Japanese Ministry of Education, Culture, Sports, Science and Technology, JSPS KAKENHI Grant Numbers 19K9983 and 18K09464.
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1186. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hinata Matsuo, Naoki Okumura, Yuya Komori, Ayumi Tokunaga, Genta Nakayama, Makiko Nakahara, Derek J Blake, Theofilos Tourtas, Ursula Schlötzer-Schrehardt, Friedrich E Kruse, Noriko Koizumi; Effect of CTG repeat expansion in TCF4 on the pathophysiology of Fuchs endothelial corneal dystrophy. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1186.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : CTG trinucleotide repeat (TNR) expansion is frequently found in TCF4 in Fuchs endothelial corneal dystrophy (FECD), and the potential involvement of TNR expansion in the pathophysiology has also been proposed. We previously reported that in FECD patients, TGF-β is highly expressed in corneal endothelial cells (CECs) and activation of TGF-β signaling induced cell death in an FECD cell model. Here we investigated the effect of CTG TNR expansion and expression of TCF4 on cell death and production of extracellular matrix production in FECD.

Methods : After obtaining patient consent, CECs were isolated from FECD patients, and then cultured and immortalized to produce an FECD cell model (iFECD). TP-PCR was used to determine the TNR length. CRISPR/Cas9 was used to delete CTG TNR (TCF4ΔCTG) or to knockout TCF4 (CTG TNR not deleted) (TCF4-/- iFECD). Cells were treated with TGF-β2 (10 ng/mL), and cell death was evaluated by phase-contrast microscopy and flow cytometry. Activation of apoptotic related proteins (caspase 3 and PARP) and expression of Snail1 and fibronectin was evaluated by western blotting. Aggresome was stained to evaluate the formation of unfolded protein.

Results : TP-PCR showed that iFECD harbored CTG repeat > 50. Phase-contrast microscopy showed that TGF-β induced cell death in iFECD and TCF4ΔCTG. However, the cell death was suppressed in TCF4-/- iFECD. Flow cytometry showed that Annexin V-positive apoptotic cells were significantly increased from 2.9% to 15.3% in iFECD and from 4.5% to 12.5% in TCF4ΔCTG by TGF-β (p<0.01). In contrast, Annexin V-positive cells were not increased by TGF-β in TCF4-/- iFECD. Western blotting showed that caspase 3 and PARP were cleaved (activated) by TGF-β in iFECD and TCF4ΔCTG, and that this activation did not occur in TCF4-/- iFECD. The expression level of Snail1 and fibronectin was increased in iFECD and TCF4ΔCTG by TGF-β. In contrast, that increased expression of Snail1 and fibronectin was suppressed in TCF4-/- iFECD. Aggresome staining showed that TGF-β mediated aggresome accumulation in iFECD and TCF4ΔCTG, but not in TCF4-/- iFECD.

Conclusions : Our current findings suggest that TCF4, but not CTG TNR expansion, is responsible for TGF-β mediated cell death in a cell model of FECD. Further study is needed to clarify the role of TCF4 and CTG TNR expansion in the pathophysiology of FECD.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×